Competing interests
DKH is supported by the NCI (R01CA281756-01A1) and the Pentecost Family Myeloma Research Center; reports research funding from Bristol Myers Squibb, Johnson & Johnson, Karyopharm, Kite Pharma, and Adaptive Biotech; and has had a consulting or advisory role for Bristol Myers Squibb, Johnson & Johnson, Legend Biotech, Pfizer, Kite Pharma/Gilead Sciences, AstraZeneca, and Karyopharm. AG-C reports honoraria from Sanofi, Pfizer, Cellectar Biosciences, and Johnson & Johnson; and consultancy with Pfizer, Cellectar Biosciences, and Johnson & Johnson. VA, HP, MS, KCDB, and ZPQ are employees and stockholders of Johnson & Johnson. MP is an employee of Legend Biotech and owns stock/stock options in Legend Biotech. KHS reports honoraria from Amgen, Bristol Myers Squibb, Johnson & Johnson, Adaptive, Sanofi, Regeneron, and Takeda; and research funding to the institution from AbbVie and Karyopharm, outside the submitted work. RB reports research funding from Johnson & Johnson, Karyopharm, AbbVie, Regeneron, and Bristol Myers Squibb; and is a member of an advisory board for Johnson & Johnson. TN reports clinical trial support (to the institution) by Novartis, clinical trial support (drug only supply to the institution) by Karyopharm; consultancy for ImmunoGen; and has served on an advisory board for Medexus. MA is a member of an advisory board for GlaxoSmithKline and Celgene; and is a member of the speakers bureau for Johnson & Johnson and GlaxoSmithKline. CLF reports honoraria/consultancy for BMS/Celgene, ONK therapeutics & Johnson & Johnson; and research funding from BMS, Johnson & Johnson, and AstraZeneca. OACP has received honoraria for consultancy from Legend Biotech USA Inc, Bristol Myers Squibb, and Johnson & Johnson. FLL reports a scientific advisory role for and consulting fees from A2, Allogene, Amgen, Bluebird Bio, BMS, Calibr, Caribou, Cowen, EcoR1, Gerson Lehrman Group (GLG), Iovance, Kite Pharma, Johnson & Johnson, Legend Biotech, Novartis, Sana, Umoja, Pfizer; has served on a data safety monitoring board for the NCI Safety Oversight CAR T-cell Therapies Committee; has received research contracts/grants from Kite Pharma (Institutional), Allogene (Institutional), CERo Therapeutics (Institutional), Novartis (Institutional), BlueBird Bio (Institutional), 2SeventyBio (Institutional), BMS (Institutional), National Cancer Institute (R01CA244328 MPI), Leukemia and Lymphoma Society Scholar in Clinical Research (PI: Locke) Patents, Royalties; has several patents held by the institution in their name (unlicensed) in the field of cellular immunotherapy; and has been involved in the following educational or editorial activities: Aptitude Health, ASH, BioPharma Communications CARE Education, Clinical Care Options Oncology, Imedex, Society for Immunotherapy of Cancer. LCP has received research funding from BMS and Johnson & Johnson.
Ethical
This multi-center study was approved by respective institutions’ Institutional Review Boards (IRBs) and an external IRB (Advarra).
